Prosecution Insights
Last updated: August 16, 2026
Application No. 16/220,925

COAXIAL GUIDE CATHETER FOR INTERVENTIONAL CARDIOLOGY PROCEDURES

Non-Final OA §103
Filed
Dec 14, 2018
Priority
May 03, 2006 — divisional of 8048032 +5 more
Examiner
WILLIAMS, CATHERINE SERKE
Art Unit
3993
Tech Center
3900
Assignee
Teleflex Incorporated
OA Round
4 (Non-Final)
64%
Grant Probability
Moderate
4-5
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
80 granted / 126 resolved
+3.5% vs TC avg
Strong +28% interview lift
Without
With
+28.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 11m
Avg Prosecution
22 currently pending
Career history
148
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
32.7%
-7.3% vs TC avg
§102
9.3%
-30.7% vs TC avg
§112
21.0%
-19.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 126 resolved cases

Office Action

§103
Notice of Pre-AIA Status The present reissue application is being examined under the pre-AIA first to invent provisions. It is noted that while the examination of the current reissue application falls under the pre-AIA first to invent provisions due to the priority date of US Patent No. 8,292,850 (the ‘850 patent); the application for reissue filing date is after September 16, 2012 and therefore is subject to the reissue rule changes enacted under the Leahy-Smith American Invents Act (AIA ), see Federal Register, Vol. 77, No. 157, pg. 48820, August 16, 2012. For reissue applications filed on or after September 16, 2012, all references to 35 U.S.C. 251 and 37 CFR 1.172, 1.175, and 3.73 are to the current provisions. Reissue Applications and Prosecution History Applicant is reminded of the continuing obligation under 37 CFR § 1.178(b), to timely apprise the Office of any prior or concurrent proceeding in which the ‘850 patent is or was involved. These proceedings would include interferences, reissues, reexaminations and litigations. The present reissue application is a reissue of the ‘850 patent and a continuation reissue of reissue application 14/984,273 resulting in US Pat. No. RE47379 which is a continuation reissue of reissue application 14/195,435 resulting in US Pat. No. RE46116 which is a continuation reissue of reissue application 14/070,161 resulting in US Pat. No. RE45380 which is a reissue of the ‘850 patent. Reissue application 14/195,385 resulting in US Pat. No. RE45760 and reissue application 14/195,413 resulting in US Pat. No. RE45776 were filed contemporaneously to reissue application 14/195,435 as copending continuation reissue applications of reissue application 14/070,161, The ‘850 patent is a DIV of US Pat. No. 8,142,413 which is a DIV of US Pat. No. 8,048,032. US Pat. No. 8,048,032 is subject to Inter Partes Reviews IPR2020-00126 and IPR2020-00127 which were instituted and each include Final Decisions mailed on 6/17/21. A Notice of Appeal was filed in both reviews on 9/27/21. US Pat. No. 8,142,413 is subject to Inter Partes Reviews IPR2020-01341 and IPR2020-01342 which have been instituted and a Final Decision was mailed on 2/07/22 in both reviews. A Notice of Appeal was filed in both reviews on 4/06/22. RE45380 is subject to Inter Partes Reviews IPR2020-00128; IPR2020-00129; and IPR2020-00130 which were instituted and include respective Final Decisions mailed on 6/17/21. A Notice of Appeal was filed in all three reviews on 9/27/21. RE45760 is subject to IPR2020-00132 and IPR2020-00134 which were instituted and each include Final Decisions mailed on 6/17/21. A Notice of Appeal was filed in both reviews on 9/27/21. RE45776 is subject to IPR2020-00135 and IPR2020-00136 which were instituted and each include Final Decisions mailed on 6/17/21. A Notice of Appeal was filed in both reviews on 9/27/21. RE46116 is subject to Inter Partes Reviews IPR2020-001343 and IPR2020-01344 which have been instituted and a Final Decision was mailed on 2/23/22 in both reviews. A Notice of Appeal was filed in both reviews on 4/22/22. RE47379 is subject to Inter Partes Reviews IPR2020-00137 and IPR2020-00138 which were instituted and a Final Decision was mailed on 6/17/21 and 6/22/21, respectively. A Notice of Appeal was filed in both reviews on 9/27/21. The CAFC Decision in the consolidated appeals in Nos. IPR2020-00126; IPR2020-00128; IPR2020-00132; IPR2020-00135; and IPR2020-00137 was decided on May 24, 2023 and the CAFC affirmed the PTAB’s Final Decision that Itou does not qualify as prior art to the challenged patents under 35 USC 102(e) and that the challenged claims are not unpatentable. The CAFC Decision in the Appeals in Nos. IPR2020-00129; IPR2020-00134; and IPR2020-00138 was decided on June 5, 2023 and the CAFC affirmed the PTAB’s Final Decision regarding the claims found not unpatentable and granting issuance of the substitute claims. The CAFC Decision in the Appeals in Nos. IPR2020-00127; IPR2020-00130; and IPR2020-00136 was decided on June 5, 2023 and the CAFC affirmed the PTAB’s Final Decision regarding the claims found not unpatentable and granting issuance of the substitute claims. The appeals of the Final Decisions in IPR2020-01341; IPR2020-01342; IPR2020-01343; and IPR2020-01344 are still pending at the CAFC as of the mailing of this office action. Applicant is further reminded of the continuing obligation under 37 CFR § 1.56 to timely apprise the Office of any information which is material to patentability of the claims under consideration in this reissue application. These obligations rest with each individual associated with the filing and prosecution of this application for reissue. See also MPEP §§ 1404, 1442.01 and 1442.04. Oath/Declaration The reissue oath/declaration filed with this application is defective because the error which is relied upon to support the reissue application is not an error upon which a reissue can be based. See 37 CFR 1.175and MPEP § 1414. The Reissue Declaration by the Inventor filed 09/18/2020 sets forth that the limitations of "A system" and "a guide catheter having a continuous lumen extending for a predefined length from a proximal end at a hemostatic valve to a distal end adapted to be placed in the branch artery, the continuous lumen of the guide catheter having a circular cross-sectional inner diameter sized such that interventional cardiology devices are insertable into and through the continuous lumen of the guide catheter" from original claim 1 of the ‘850 patent caused the ‘850 patent to be in error. However, these limitations were previously relied upon in the error statements as the basis of a reissue proceeding in reissue applications 14/070,161; 14/195,385; 14/195,413; 14/195,435 and 14/984,273. Therefore, this error is considered to have already been corrected in the issuance of Reissue Pat. Nos. RE45380; RE45760; RE45776; RE46116 and RE47379. Specifically, each of these reissue patents issued with claims either amending or entirely eliminating the same limitations being relied upon again as causing an error as the basis for reissue of the ‘850 patent. Additionally, the same error, i.e. original claim limitations causing the error, is being relied upon in this reissue as is being relied upon in each of co-pending reissue applications 16/184,706; 16/220,951, 16/220,996 and 16/220,975. While, the issuance of multiple reissue patents from a single original patent is permitted. See 37 CFR 1.177; once a reissue claim has gone to issuance, the error providing the basis for that reissue patent is considered to have been corrected. If the same error corrected in the parent, e.g. reissue application 14/070,161 resulting in Pat. No. RE45380, is also being corrected in a continuation reissue application, but the error is being corrected in a different way, a statement is needed to explain compliance with 37 CFR 1.175(f)(2) for a reissue application filed on or after September 16, 2012. Since the current error statement relies on the same limitations listed in each of applications 14/070,161; 14/195,385; 14/195,413; 14/195,435; 14/984,273; 16/184,706; 16/220,951; 16/220,996 and 16/220,975, the statement explaining that the error is being corrected in a different way would need to differentiate from each of these applications. Claims 25-58 are rejected as being based upon a defective reissue declaration error statement under 35 U.S.C. 251 as set forth above. See 37 CFR 1.175. The nature of the defect(s) in the error statement is set forth in the discussion above in this Office action. Double Patenting The nonstatutory double patenting rejections have been withdrawn in light of the Terminal Disclaimer filed and approved 4/16/21. Response to Arguments Applicant’s arguments, see Remarks, filed 04/16/2021, with respect to claims 25-58 have been fully considered and are persuasive. The rejection of Claims 25-26, 34, 41, 43, and 46-50 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over US Pat. No. 5,439,445 to Kontos (“Kontos”) in view of US Pub. No. 2004/0010280 to Adams (“Adams ‘280”) has been withdrawn in light of the remarks filed 04/16/2021. The rejection of claims 25, 27-28, 34-35, 41-42, 45-46 and 51-52 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Kontos in view of Adams ‘280 and in further view of US Pub. No. 2005/0015073 to Kataishi et al. (“Kataishi”) has been withdrawn in light of the remarks filed 04/16/2021. The rejection of claims 30-33, 37-40 and 55-58 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Kontos in view of Adams ‘280 with or without Kataishi and in further view of US Pat. No. 5,911,715 to Berg (“Berg”) has been withdrawn in light of the remarks filed 04/16/2021. The rejection of claims 25-27, 29, 34, 41, 43-44, 46, 47-50 and 53-54 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Kontos in view of Adams ‘280 in further view of US Patent No. 7,604,612 to Ressemann et al. (“Ressemann”) has been withdrawn in light of the remarks filed 04/16/2021. The rejection of claims 25-28; 34-36, 41, 42, 43, 45-46 and 48, 49, 50, 51,52 under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Kontos in view of Adams ‘280 and Ressemann and in further view of Kataishi has been withdrawn. The rejection of claims 25-28; 34-36, 41,42,43, 45-46 and 48-51, 52 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Kontos in view of Adams ‘280 and Ressemann and in further view of US Pat. No. 5,980,486 to Enger (“Enger”) has been withdrawn. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE SERKE WILLIAMS whose telephone number is (571)272-4970. The examiner can normally be reached Monday through Friday core hours 8am-4pm ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Eileen Lillis can be reached on 571-272-6928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CATHERINE S WILLIAMS/Reexamination Specialist, Art Unit 3993 Conferees: /Patricia L Engle/Reexamination Specialist, Art Unit 3993 /EILEEN D LILLIS/SPRS, Art Unit 3993
Read full office action

Prosecution Timeline

Show 5 earlier events
Apr 16, 2021
Response Filed
Jan 16, 2024
Non-Final Rejection mailed — §103
Mar 14, 2024
Examiner Interview Summary
Apr 16, 2024
Response Filed
Aug 06, 2024
Request for Continued Examination
Aug 06, 2024
Response after Non-Final Action
Aug 07, 2024
Response after Non-Final Action
Aug 14, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent RE50949
TEXTURED WOVEN FABRIC FOR USE IN IMPLANTABLE BIOPROSTHESES
3y 1m to grant Granted Jul 14, 2026
Patent RE50944
MONITORING UNIT
3y 3m to grant Granted Jul 07, 2026
Patent 12663629
SYSTEMS AND METHODS FOR TREATING HEARING LOSS
3y 2m to grant Granted Jun 23, 2026
Patent 12629476
SINGLE-USE SYRINGE WITH SYRINGE LOCK
3y 3m to grant Granted May 19, 2026
Patent RE50885
ENDOSCOPIC PROBE WITH REDUCED OBSTRUCTION
3y 2m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

4-5
Expected OA Rounds
64%
Grant Probability
92%
With Interview (+28.4%)
2y 11m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 126 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month